THE RELATIONSHIP BETWEEN R&D EXPENSES AND PIPELINE DRUGS
Which developments and trends can be identified with regard to R&D spending in the pharmaceutical industry since 2015 and how does this relate to the number of drugs in the pipeline?
Our research shows: Continuously increasing R&D spendings contrast with a reduction in the pipeline. To stay at the top, be innovative, and to meet increasing regulatory requirements, companies have to continuously optimize their R&D efforts.